Trial Profile

Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
Indications Obesity; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms DECREASE

Most Recent Events

03 Feb 2022 Results investigating the separate and combined effects of dapagliflozin and exenatide on the CNS in participants with obesity and type 2 diabetes published in the Journal of Clinical Endocrinology and Metabolism
01 Aug 2021 Results of prespecified secondary analysis published in the Diabetes, Obesity and Metabolism
08 Jun 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com